Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922632 · ClinicalTrials.gov registry record · NA
Data-driven Approaches to Healthcare Provider Resilience & Burnout During COVID-19
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 212
- Enrollment target
NCT04922632: Clinical Trial NA study, sponsored by Duke University.
NCT04922632 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 212 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04922632, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 212 participants
- Enrollment target
Study Summary
The United States is battling dual pandemics: healthcare provider (HCP) exhaustion and COVID-19. The COVID-19 pandemic death toll has surpassed 595,000 and continues to climb as the worldwide outbreak continues. Moreover, we have yet to understand the health impacts of "long-COVID". As evidenced by the national burnout epidemic in HCPs, persistent workplace stress not only impacts personal provider wellbeing, but also influences effective practice and patient outcomes. To address this need, we propose a 4-year, multi-site, four-arm parallel-group randomized clinical trial (RCT) comparing 2 non-pharmacological interventions: Transcendental Meditation (TM) and Experience Resolution Methodology (ERM) to Treatment as Usual (TAU). Participation in this study lasts up to 24 months for enrolled participants and is considered minimal risks.
Primary Outcome
The Connor-Davidson Resilience scale (CD-RISC) comprises of 25 items, each rated on a 5-point scale (0-4), with higher scores reflecting greater resilience
Interventions
- BEHAVIORAL Treatment As Usual (TAU)
- BEHAVIORAL Transcendental Meditation (TM)
- BEHAVIORAL Experience Resolution Methodology (ERM)
- BEHAVIORAL Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2023-03-12 |
| Phase | NA |
Why NCT04922632 stopped before completion
NCT04922632 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which Treatment As Usual (TAU) is the first listed.
NCT04922632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04922632 about?
NCT04922632 is a clinical study titled "Data-driven Approaches to Healthcare Provider Resilience & Burnout During COVID-19". The United States is battling dual pandemics: healthcare provider (HCP) exhaustion and COVID-19. The COVID-19 pandemic death toll has surpassed 595,000 and continues to climb as the worldwide outbreak continues. Moreover, we have yet to understand the health impacts of "long-COVID". As evidenced by ...
What is the current status of trial NCT04922632?
This trial is currently terminated. It is a NA study. The enrollment target is 212 participants. The study started on 2022-02-21. Estimated completion is 2023-03-12.
What interventions are being tested in trial NCT04922632?
The interventions under investigation include: Treatment As Usual (TAU) (BEHAVIORAL), Transcendental Meditation (TM) (BEHAVIORAL), Experience Resolution Methodology (ERM) (BEHAVIORAL), Transcendental Meditation (TM) and Experience Resolution Methodology (ERM) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04922632?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04922632's enrollment target sits among peer trials
212 489th of 2000 higher than 1,511 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI